A disintegrin and metalloproteinase (ADAM)-10 as a predictive factor for tocilizumab effectiveness in rheumatoid arthritis |
| |
| Authors: | Takeo Isozaki Shinichiro Nishimi Airi Nishimi Mayu Saito Yusuke Miwa Yoichi Toyoshima |
| |
| Affiliation: | 1. Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan and;2. Department of Orthopedics, Showa University School of Medicine, Tokyo, Japan |
| |
| Abstract: | Objectives: A disintegrin and metalloproteinase (ADAM)-10 is expressed in rheumatoid arthritis (RA). In this study, we focused on ADAM-10 as a predictive factor for the treatment with biologics in RA.Methods: The levels of ADAM-10 and fractalkine/CX3CL1 in RA and healthy controls serum were measured using enzyme-linked immunosorbent assays. Fifteen patients were treated with adalimumab (ADA), and 20 patients were treated with tocilizumab (TCZ).Results: ADAM-10 positively correlated with fractalkine/CX3CL1 in the sera of RA patients and was presented at a significantly higher level compared to that in normal serum (487?±?80?pg/ml and 85?±?33?pg/ml, respectively, p?Conclusions: ADAM-10 may be a predictor of the effectiveness of TCZ in treating RA. |
| |
| Keywords: | Adalimumab ADAM-10 Predictive factor Rheumatoid arthritis Tocilizumab |
|
|
